Axena Health

Coming – September 23

Clinically De-risked, Commercially Scaling, Med Device For 28 Million Women

Date and Time

September 23

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

28 million U.S. women have moderate-to-severe urinary incontinence, yet fewer than 7% of diagnosed patients receive recommended first-line supervised pelvic floor muscle training.

Axena Health is a commercial-stage women’s health company focused on transforming the treatment of urinary incontinence. Its flagship Leva® Pelvic Health System is an FDA-cleared at-home medical device that guides women through pelvic floor muscle training using a motion-sensing intravaginal device connected to a smartphone app.

Available via a prescription, patients complete just five minutes of therapy per day for 12 weeks, while the platform provides real-time feedback, coaching, adherence support, and reports progress back to prescribing clinicians.

Leva® is supported by extensive peer-reviewed clinical evidence demonstrating durable outcomes. Axena has expanded to approximately 50 million covered lives, generated $3.8 million in 2025, is on track to exceed $6 million in 2026, and has the commercial infrastructure in place to accelerate growth exponentially in the years ahead.

The company is also collaborating with Mayo Clinic on clinical integration and AI-enabled precision care, creating additional opportunities to expand the platform across women’s pelvic health.

Register to reserve your space for this 30-minute, executive briefing with Axena CEO and Chief Medical Officer, Dr. Samantha Pulliam, to hear the impact this important innovation can have on the lives of millions of women.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.